Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder
| Autor: | Junichi Fujita, Hideki Negoro, Masahide Usami, Takashi Okada, Noa Tsujii, Hidenori Kuwabara, Takuya Saito, Junzo Iida, Michiyo Kawamura |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pediatrics
medicine.medical_specialty Adolescent Psychological intervention Cochrane Library law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Quality of life law mental disorders medicine Humans Attention deficit hyperactivity disorder 0501 psychology and cognitive sciences 050102 behavioral science & comparative psychology Child business.industry Remission Induction 05 social sciences medicine.disease 030227 psychiatry Psychiatry and Mental health Systematic review Attention Deficit Disorder with Hyperactivity Strictly standardized mean difference Meta-analysis Quality of Life Central Nervous System Stimulants business |
| Zdroj: | The Journal of Clinical Psychiatry. 81 |
| ISSN: | 1555-2101 |
| Popis: | Objective This study aimed to compare the effect of continuing and discontinuing medications on quality of life of patients with attention-deficit/hyperactivity disorder (ADHD). Data sources PubMed, Cochrane Library, and Embase databases were searched using generic terms for ADHD, discontinuing, continuing, pharmacotherapy, and randomized controlled trials without date or language restrictions. Study selection Of the 3,672 screened studies, 9 met the predefined inclusion criteria on patients with ADHD; 5 of these 9 studies reporting on 1,463 patients (children and adolescents, n = 894; adults, n = 569) measured quality of life and were included in this meta-analysis. Only randomized, double-blind, placebo-controlled withdrawal trials of ADHD medications were included. Data extraction Data were independently extracted according to the Cochrane Handbook for Systematic Reviews of Interventions. Analyses were based on random-effects models. Results Compared with continuing medications, discontinuing them significantly worsened quality of life score in patients with ADHD (standardized mean difference [SMD] = 0.19; 95% CI, 0.08 to 0.30]). Moreover, discontinuing medications worsened this score in children and adolescents with ADHD (SMD = 0.21; 95% CI, 0.06 to 0.36) but not in adults with ADHD (SMD = 0.02; 95% CI, -0.46 to 0.50). Conclusions Discontinuing medications was associated with a small but statistically significant decrease in quality of life among children and adolescents with ADHD but not in adults with ADHD. Quality of life can be applied in pharmacologic interventions regarding continuing and discontinuing medication because this concept is related to individuals' appraisal of their situation. Quality of life is an important factor for planning individualized ADHD medication treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|